First and only immunotherapy to demonstrate survival benefit in this setting in a global Phase III trial
The FDA assigned a Prescription Drug User Fee Act (PDUFA) goal date of June 21, 2024
Combination shows consistent benefit across prespecified post-progression outcomes
The U.S. FDA recently approved Xolair as the first and only medicine for children and adults with one or more food allergies
The US FDA's clearance of the trial marks the first global registrational Phase III trial for olverembatinib in patients with CP-CML to be conducted.
This Phase III clinical trial is a randomized, double-blind, placebo-controlled, multicenter clinical trial in China to evaluate the safety and efficacy of ASC40
If approved, Xolair would be the first medicine to reduce allergic reactions to multiple foods following an accidental exposure
Studies have demonstrated that ZYIL1 is highly potent and can suppress inflammation caused by NLRP3 inflammasome activation
STABILIZE-CKD and DIALIZE-Outcomes trials are part of the CRYSTALIZE evidence programme
Blenrep (belantamab mafodotin) plus BorDex showed statistically significant progression-free survival (PFS) benefit versus daratumumab plus BorDex
Subscribe To Our Newsletter & Stay Updated
